• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Goals













All true. Big increase was expected but if they have the money for this expansion they should have it to pay a good bonus to reps that do well and not make it unreachable. Pissed off a lot of people with the goals and all the other stuff happening.
 




All true. Big increase was expected but if they have the money for this expansion they should have it to pay a good bonus to reps that do well and not make it unreachable. Pissed off a lot of people with the goals and all the other stuff happening.

They could care less if your goals are unrealistic. It saves them on bonus payout when you don’t hit them.
 








With the new shift at the top in the psych business unit, what’s next for reps? Nothing as of today but wish they would be more open. Not hitting goals with Rex, the launch didn’t go as planned last year, Trintellix isn’t much longer with patent and now waiting for another indication hopefully for Rex. Just feels like more to come down in near future? And they are putting more into migraine with new openings.
 




With the new shift at the top in the psych business unit, what’s next for reps? Nothing as of today but wish they would be more open. Not hitting goals with Rex, the launch didn’t go as planned last year, Trintellix isn’t much longer with patent and now waiting for another indication hopefully for Rex. Just feels like more to come down in near future? And they are putting more into migraine with new openings.
You so smart